First-in-human administration of [¹⁶¹Tb]Tb-SibuDAB and comparative dosimetry with standard [¹⁷⁷Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study

Affiliations

• ¹ Division of Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland.
• ² Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
• ³ PSI Center for Life Sciences, Villigen-PSI, Canton of Aargau, Switzerland.
• ⁴ Department of Biology, Institute for Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
• ⁵ Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden.
• ⁶ PSI Center for Nuclear Engineering and Sciences, Villigen-PSI, Canton of Aargau, Switzerland.
• ⁷ Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
• ⁸ Division of Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland. damian.wild@usb.ch.